Skip to main content

Table 3 Indications for routine amniocentesis. Every indication was counted once but many cases had more than one indication.

From: The application of late amniocentesis: a retrospective study in a tertiary fetal medicine center in China

Indication

Number

Percentage

(%)

Pathogenic

Results

Diagnostic

Yield (%)

VUS

Fetal abnormalities

979

45.0

125

12.8

35

Increased NT

308

14.1

43

14.0

8

Cardiovascular malformations

148

6.8

19

12.8

8

Central nervous system malformations

134

6.2

11

8.2

3

Multiple malformations

96

4.4

32

33.3

3

Urogenital malformations

81

3.7

5

6.2

5

Facial malformations

66

3.0

4

6.1

3

Skeletal malformations

47

2.2

2

4.3

0

Digestive malformations

21

1.0

1

4.8

0

FGR

20

0.9

1

5.0

0

Fetal tumor

19

0.9

4

21.1

1

Chest malformations

16

0.7

2

12.5

0

Polyhydramnios

8

0.4

1

12.5

0

Oligohydramnios

6

0.3

0

0

0

Ascites

5

0.2

0

0

0

Placental anomalies

4

0.2

0

0

4

Suspected prenatal screening results

612

28.1

177

28.9

26

Abnormal NIPT result

436

20.0

167

38.3

19

Positive second trimester DS screening result

176

8.1

10

5.7

7

Abnormal diagnostic test results

36

1.7

9

25

2

Abnormal CMA result

21

1.0

6

28.6

1

Abnormal karyotyping result

15

0.7

3

20.0

1

Others

549

25.2

23

4.2

26

Abnormal tribunal history

188

8.6

8

4.3

8

Advanced maternal age

163

7.5

8

4.9

8

Family history of genetic disease

102

4.7

3

2.9

6

Patient’s request

96

4.4

4

4.2

4

Total

2177

100

334

15.3

89

  1. Abbreviations: FGR Fetal growth restriction, defined as an estimated weight less than the 10th percentile [13]; Polyhydramnios defined as an amniotic fluid index (AFI) > 24 cm or the maximum pool depth (MPD) is > 8 cm; Oligohydramnios defined as a value of AFI < 5 cm or MPD < 2 cm; NT Nuchal translucency; Increased NT defined as NT measurement reaches 3.5 mm or more (>99th percentile) [14]; NIPT Noninvasive prenatal testing